Vor Biopharma, Inc. VOR 深 滬
等待開盤 08-14 09:30:00 美东时间
2.02
+0.360
+21.69%
華盛通- 最 高2.30
- 今 開2.07
- 成交量 2765.02万股
- 最 低 1.95
- 昨 收 1.66
- 總市值 2.53亿
- 52周最高 3.29
- 市盈率 靜 --
- 換手率 22.12%
- 52周最低 0.1311
- 委 比 -76.74%
- 總股本 1.25亿
- 歷史最高 63.62
- 量 比 8.03
- 振 幅 21.08%
- 歷史最低 0.1311
- 每 手 1
- 風險率 0.59%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多港股创新药再迎利好催化，香港医药ETF(513700)涨近1%
港股创新药再迎利好催化，荣昌生物昨日发布公告，该公司自主研发的BLyS/APRIL双靶点融合蛋白创新药泰它西普用于治疗原发性干燥综合征...
今天 11:49
Vor Bio Rallies On Strong Data For Autoimmune Drug Candidate
Vor Bio shares climb as RemeGen's Phase 3 study in China shows telitacicept improves disease activity in primary Sjögren's disease.
08-13 23:15
Vor Biopharma shares are trading higher following the release of its Q2 reported financial results.
Vor Biopharma shares are trading higher following the release of its Q2 reporte...
08-13 20:28
Telitacicept Achieved Primary Endpoint in Phase 3 Clinical Study for Primary Sjögren's Disease with Telitacicept, a Dual BAFF/APRIL Inhibitor
Vor Bio and RemeGen achieved positive Phase 3 results for telitacicept in treating primary Sjögren's disease, meeting the primary endpoint of improving disease activity. The treatment demonstrated a favorable safety profile and potential as a best-in-disease option. RemeGen plans to submit a Biologics License Application (BLA) in China, with telitacicept targeting global expansion. Data will be presented at an upcoming medical conference.
08-13 12:30
Vor Biopharma Q2 Adj. EPS $(2.19) Misses $(0.22) Estimate
Vor Biopharma (NASDAQ:VOR) reported quarterly losses of $(2.19) per share which missed the analyst consensus estimate of $(0.22) by 877.68 percent. This is a 434.15 percent decrease over losses of $(0.41) per share from
08-13 05:54
Vor Bio Appoints Seasoned Biotech Executive Dallan Murray as Chief Commercial Officer
Vor Bio has appointed Dallan Murray as Chief Commercial Officer to lead the global market readiness and launch strategy for telitacicept, a novel treatment for autoimmune diseases. Murray, with over 25 years of experience in biotech and pharma, joins from Sarepta Therapeutics, where he oversaw significant product launches, including the first RNA and gene therapies. He will focus on preparing for telitacicept's global commercialization, currently...
08-04 12:30
Vor Biopharma Announces Key Leadership Changes
An update from Vor Biopharma ( ($VOR) ) is now available. On July 17, 2025, Vor...
07-23 05:31
Sarepta's Shocking Stand: Company Rejects FDA Request To Pull Gene Therapy Elevidys
FDA places clinical hold on Sarepta's LGMD gene therapy trials after three deaths and revokes platform tech designation due to safety concerns.
07-21 19:45
Vor Bio Appoints Biotech Industry Leaders Alexander (Bo) Cumbo and Michel Detheux, Ph.D. to Board of Directors
Vor Bio announced the appointment of Alexander (Bo) Cumbo and Michel Detheux, Ph.D., to its Board of Directors. Bo Cumbo, CEO of Solid Biosciences, brings over 30 years of commercial and executive leadership in biotech. Michel Detheux, CEO of iTeos Therapeutics, has extensive experience in drug development and partnerships, including a $2 billion deal with GSK. Their expertise will support Vor Bio's advancement of telitacicept for autoimmune dise...
07-21 12:30
Sarepta Therapeutics' Reorganization Boosts Investor Confidence
Sarepta agrees to FDA's black box warning and announces major restructuring, including job cuts and cost-saving measures to meet 2027 goals.
07-18 00:10
